New chin filler technique aims for safer, better results

NCT ID NCT07193199

Completed Symptom relief Sponsor: Erevna Innovations Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study tests a hyaluronic acid filler called Revanesse Sculpt+ along with a new injection method for people with a receding chin. Twenty-one adults will receive the treatment and be followed for 12 months to see if their chin projection improves. The goal is to achieve better aesthetic results with fewer side effects like filler migration or lumps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Revanesse Sculpt+ (hyaluronic acid filler)
What this could lead to: If successful, this could offer a safer, more effective option for chin augmentation with fewer side effects like product migration or lumps.
What could go wrong: This is a small, non-randomized study with no control group, so results may not apply broadly. The filler is already approved in Canada, but the new technique needs more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AESTHETIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AESTHETIC

Contacts and locations

Locations

Erevna Innovations Inc.

Montreal, Quebec, H3Z 1C3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.